scholarly article | Q13442814 |
P50 | author | Katerina Politi | Q66809333 |
Fred R Hirsch | Q89864676 | ||
Kenichi Suda | Q42316056 | ||
P2093 | author name string | Hui Yu | |
Tetsuya Mitsudomi | |||
Koh Furugaki | |||
Christopher J Rivard | |||
Kim Ellison | |||
Leslie Rozeboom | |||
Mary Ann C Melnick | |||
P2860 | cites work | Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. | Q51372253 |
Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer. | Q54339119 | ||
Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysis | Q79209903 | ||
Subsets of epidermal growth factor receptors during activation and endocytosis | Q24317697 | ||
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. | Q33819404 | ||
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer | Q36801144 | ||
Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation--diversity, ductility, and destiny | Q38021967 | ||
Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity. | Q38486882 | ||
Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells | Q38746756 | ||
PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer | Q38804050 | ||
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review | Q38867118 | ||
EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. | Q38872276 | ||
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation | Q38912283 | ||
New and emerging targeted treatments in advanced non-small-cell lung cancer. | Q38947183 | ||
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer | Q38975751 | ||
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project | Q39135152 | ||
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer | Q40241719 | ||
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis. | Q41112103 | ||
Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor | Q42807646 | ||
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer | Q42815191 | ||
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. | Q48020812 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P4510 | describes a project that uses | ImageQuant | Q112270642 |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 7694202 | |
P577 | publication date | 2017-10-08 | |
P1433 | published in | BioMed Research International | Q17509958 |
P1476 | title | Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines | |
P478 | volume | 2017 |
Q91937343 | Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer |
Q97537416 | Inter-tumor heterogeneity of PD-L1 status: is it important in clinical decision making? |
Q92942818 | MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer |
Q98291341 | PD-L1 Under Regulation of miR-429 Influences the Sensitivity of Gastric Cancer Cells to TRAIL by Binding of EGFR |
Search more.